PURPOSE: The purpose of this study was to analyze the probability and time course of fibrotic changes in breast reconstruction before or after postmastectomy radiotherapy (PMRT). MATERIALS AND METHODS: Between 1995 and 2004, 109 patients were treated with PMRT at Tübingen University and underwent heterologous (HL) or autologous (AL) breast reconstruction prior or subsequent to radiation therapy. Fibrosis of the reconstructed breast after radiotherapy was assessed using the Baker score for HL reconstructions and the Common Terminology Criteria for Adverse Events (CTCAE) for all patients. Actuarial rates of fibrosis were calculated for the maximum degree acquired during follow- up and at the last follow-up visit documented. RESULTS: Median time to follow-up was 34 months (3-227 months). Radiotherapy was applied with a median total dose of 50.4 Gy. A total of 44 patients (40.4%) received a boost treatment with a median dose of 10 Gy. Breast reconstruction was performed with AL, HL, or combined techniques in 20, 82, and 7 patients, respectively. The 3-year incidence of ≥ grade III maximum fibrosis was 20% and 43% for Baker and CTCAE scores, respectively. The corresponding figures for fibrosis at last follow-up visit were 18% and 2%. The 3-year rate of surgical correction of the contralateral breast was 30%. Initially unplanned surgery of the reconstructed breast was performed in 39 patients (35.8%). Boost treatment and type of cosmetic surgery (HL vs. AL) were not significantly associated with the incidence of fibrosis. CONCLUSIONS: We found severe fibrosis to be a frequent complication after PMRT radiotherapy and breast reconstruction. However, surgical intervention can ameliorate the majority of high grade fibrotic events leading to acceptable long-term results. No treatment parameters associated with the rate of fibrosis could be identified.
PURPOSE: The purpose of this study was to analyze the probability and time course of fibrotic changes in breast reconstruction before or after postmastectomy radiotherapy (PMRT). MATERIALS AND METHODS: Between 1995 and 2004, 109 patients were treated with PMRT at Tübingen University and underwent heterologous (HL) or autologous (AL) breast reconstruction prior or subsequent to radiation therapy. Fibrosis of the reconstructed breast after radiotherapy was assessed using the Baker score for HL reconstructions and the Common Terminology Criteria for Adverse Events (CTCAE) for all patients. Actuarial rates of fibrosis were calculated for the maximum degree acquired during follow- up and at the last follow-up visit documented. RESULTS: Median time to follow-up was 34 months (3-227 months). Radiotherapy was applied with a median total dose of 50.4 Gy. A total of 44 patients (40.4%) received a boost treatment with a median dose of 10 Gy. Breast reconstruction was performed with AL, HL, or combined techniques in 20, 82, and 7 patients, respectively. The 3-year incidence of ≥ grade III maximum fibrosis was 20% and 43% for Baker and CTCAE scores, respectively. The corresponding figures for fibrosis at last follow-up visit were 18% and 2%. The 3-year rate of surgical correction of the contralateral breast was 30%. Initially unplanned surgery of the reconstructed breast was performed in 39 patients (35.8%). Boost treatment and type of cosmetic surgery (HL vs. AL) were not significantly associated with the incidence of fibrosis. CONCLUSIONS: We found severe fibrosis to be a frequent complication after PMRT radiotherapy and breast reconstruction. However, surgical intervention can ameliorate the majority of high grade fibrotic events leading to acceptable long-term results. No treatment parameters associated with the rate of fibrosis could be identified.
Authors: E A Krueger; E G Wilkins; M Strawderman; P Cederna; S Goldfarb; F A Vicini; L J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-01 Impact factor: 7.038
Authors: S J Victor; D M Brown; E M Horwitz; A A Martinez; V R Kini; J E Pettinga; K W Shaheen; P Benitez; P Y Chen; F A Vicini Journal: Cancer Date: 1998-04-01 Impact factor: 6.860
Authors: Ashish K Chawla; Lisa A Kachnic; Alphonse G Taghian; Andrzej Niemierko; Daniel T Zapton; Simon N Powell Journal: Int J Radiat Oncol Biol Phys Date: 2002-10-01 Impact factor: 7.038
Authors: Peter G Cordeiro; Andrea L Pusic; Joseph J Disa; Beryl McCormick; Kimberly VanZee Journal: Plast Reconstr Surg Date: 2004-03 Impact factor: 4.730
Authors: Marc D Piroth; Daniela M Piroth; Michael Pinkawa; Seth G Woodruff; Richard Holy; Michael J Eble Journal: Strahlenther Onkol Date: 2009-10-06 Impact factor: 3.621
Authors: S Subramaniam; S Thirumalaiswamy; C Srinivas; G A Gandhi; M Kathirvel; K K Kumar; S Mallik; M Babaiah; Y Pawar; A Clivio; A Fogliata; P Mancosu; G Nicolini; E Vanetti; L Cozzi Journal: Strahlenther Onkol Date: 2012-03-10 Impact factor: 3.621
Authors: Jan Kriz; Oliver Micke; Frank Bruns; Uwe Haverkamp; Ralph Mücke; Ulrich Schäfer; Heinrich Seegenschmiedt; Rolf-Peter Müller; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2011-03-07 Impact factor: 3.621
Authors: Marianne Linthorst; Tomas Drizdal; Hans Joosten; Gerard C van Rhoon; Jacoba van der Zee Journal: Strahlenther Onkol Date: 2011-11-25 Impact factor: 3.621
Authors: Thomas Hehr; René Baumann; Wilfried Budach; Marciana-Nona Duma; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; David Krug; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederick Wenz; Rolf Sauer Journal: Strahlenther Onkol Date: 2019-08-26 Impact factor: 3.621
Authors: Mimi R Borrelli; Abra H Shen; Gordon K Lee; Arash Momeni; Michael T Longaker; Derrick C Wan Journal: Ann Plast Surg Date: 2019-10 Impact factor: 1.539